NASDAQ:PTEPolarityte Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Polarityte Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.98 -0.03 (-2.98 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$0.92Now: $0.98▼$1.0150-Day Range$0.82MA: $0.97▼$1.1552-Week Range$0.78Now: $0.98▼$6.72Volume453,844 shsAverage Volume581,762 shsMarket Capitalization$37.55 millionP/E RatioN/ADividend YieldN/ABeta1.68 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingPolarityte has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.40, Polarityte has a potential upside of 453.1% from its current price of $0.98.Amount of Analyst CoveragePolarityte has only been the subject of 4 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesPolarityte has received 122 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPolarityte has received 105 “underperform” votes. (Add your “underperform” vote.)Community SentimentPolarityte has received 53.74% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Polarityte and other stocks. Vote “Outperform” if you believe PTE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPolarityte does not currently pay a dividend.Dividend GrowthPolarityte does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Polarityte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $52,321.00 in company stock.Percentage Held by InsidersOnly 8.38% of the stock of Polarityte is held by insiders.Percentage Held by InstitutionsOnly 27.34% of the stock of Polarityte is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Polarityte are expected to grow in the coming year, from ($1.58) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Polarityte is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Polarityte is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPolarityte has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.45 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTE Previous Symbol CUSIPN/A CIKN/A Webwww.polarityte.com Phone385-237-2279Debt Debt-to-Equity Ratio0.06 Current Ratio3.70 Quick Ratio3.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.65 million Price / Sales6.65 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.69Profitability EPS (Most Recent Fiscal Year)($3.70) Net Income$-92,490,000.00 Net Margins-1,561.72% Return on Equity-157.30% Return on Assets-116.60%Miscellaneous Employees153 Outstanding Shares38,460,000Market Cap$37.55 million Next Earnings DateN/A OptionableOptionable NASDAQ:PTE Rates by TradingView Receive PTE News and Ratings via Email Sign-up to receive the latest news and ratings for PTE and its competitors with MarketBeat's FREE daily newsletter. Polarityte (NASDAQ:PTE) Frequently Asked Questions How has Polarityte's stock been impacted by COVID-19 (Coronavirus)? Polarityte's stock was trading at $1.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PTE shares have decreased by 8.7% and is now trading at $0.9764. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Polarityte? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Polarityte in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Polarityte. How were Polarityte's earnings last quarter? Polarityte Inc (NASDAQ:PTE) posted its quarterly earnings data on Monday, May, 11th. The company reported ($0.39) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.57) by $0.18. The business earned $0.93 million during the quarter, compared to analysts' expectations of $1.27 million. Polarityte had a negative return on equity of 157.30% and a negative net margin of 1,561.72%. During the same period last year, the business earned ($1.18) EPS. View Polarityte's earnings history. What price target have analysts set for PTE? 5 analysts have issued twelve-month price targets for Polarityte's stock. Their forecasts range from $3.00 to $8.00. On average, they anticipate Polarityte's stock price to reach $5.40 in the next year. This suggests a possible upside of 453.1% from the stock's current price. View analysts' price targets for Polarityte. Has Polarityte been receiving favorable news coverage? News articles about PTE stock have trended negative on Monday, according to InfoTrie. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Polarityte earned a coverage optimism score of -2.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutPolarityte. Who are some of Polarityte's key competitors? Some companies that are related to Polarityte include Cidara Therapeutics (CDTX), Surface Oncology (SURF), X4 Pharmaceuticals (XFOR), Gamida Cell (GMDA), Solid Biosciences (SLDB), BIONDVAX PHARMA/S (BVXV), La Jolla Pharmaceutical (LJPC), Applied Genetic Technologies (AGTC), Champions Oncology (CSBR), Windtree Therapeutics (WINT), Outlook Therapeutics (OTLK), Neon Therapeutics (NTGN), Organovo (ONVO), AIM ImmunoTech (AIM) and Genocea Biosciences (GNCA). View all competitors. What other stocks do shareholders of Polarityte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Polarityte investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Outlook Therapeutics (OTLK), Unum Therapeutics (UMRX), BioNano Genomics (BNGO), Seanergy Maritime (SHIP), Ekso Bionics (EKSO), Matinas BioPharma (MTNB), OrganiGram (OGI) and Titan Pharmaceuticals (TTNP). Who are Polarityte's key executives? Polarityte's management team includes the following people: Mr. David B. Seaburg, Chief Exec. Officer (Age 50, Pay $7.5k)Dr. Edward Winslow Swanson, Chief Translational Medicine Officer & Co-Founder (Age 35, Pay $400k)Mr. Paul Elliot Mann, Exec. OfficerMr. Richard Hague, Pres & COO (Age 60)Mr. Jacob Alexander Patterson, Interim Chief Financial Officer What is Polarityte's stock symbol? Polarityte trades on the NASDAQ under the ticker symbol "PTE." Who are Polarityte's major shareholders? Polarityte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.30%), Sabby Management LLC (0.91%), State Street Corp (0.82%), Geode Capital Management LLC (0.81%), Advisor Group Holdings Inc. (0.50%) and Levin Capital Strategies L.P. (0.40%). Company insiders that own Polarityte stock include Cameron J Hoyler, David B Seaburg, Denver Lough, Edward Winslow Swanson, Paul Elliot Mann, Peter A Cohen, Rainer M Erdtmann, Richard Hague and Steve Gorlin. View institutional ownership trends for Polarityte. Which major investors are buying Polarityte stock? PTE stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, Advisor Group Holdings Inc., BlackRock Inc., State Street Corp, Geode Capital Management LLC, Levin Capital Strategies L.P., LWS Wealth Advisors Inc., and Capital Wealth Alliance LLC. Company insiders that have bought Polarityte stock in the last two years include Edward Winslow Swanson, Paul Elliot Mann, Peter A Cohen, and Rainer M Erdtmann. View insider buying and selling activity for Polarityte. How do I buy shares of Polarityte? Shares of PTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Polarityte's stock price today? One share of PTE stock can currently be purchased for approximately $0.98. How big of a company is Polarityte? Polarityte has a market capitalization of $37.55 million and generates $5.65 million in revenue each year. The company earns $-92,490,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Polarityte employs 153 workers across the globe. What is Polarityte's official website? The official website for Polarityte is www.polarityte.com. How can I contact Polarityte? Polarityte's mailing address is 123 NORTH WRIGHT BROTHERS DRIVE, SALT LAKE CITY UT, 84116. The company can be reached via phone at 385-237-2279 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
